Tate & Lyle issues the following trading update.
Group profit before tax in the third quarter of the year to 31 March 2004 has been in line with our expectations.
At Staley in the US, whilst some of the 2004 sweetener sales contracts have been completed at increased prices, the negotiation of major contracts is ongoing and may take some weeks to conclude. These contracts, which are being negotiated against a background of recent corn price rises, will influence the final outcome on sweetener product margins. Gains in citric acid selling prices have seen this product line return to profit.
Negotiation of Amylum’s annual contracts is not yet finished. Raw material costs in Europe, which had increased markedly at the time of our interim announcement on the 6 November 2003, have continued to rise significantly. These have reduced margins on Amylum’s contracts agreed at that time and subsequent pricing has not fully recovered higher net raw material costs. This has been exacerbated by recently increased competitive pressures and by weaker vital wheat gluten prices so that results from Amylum for 2004 will be below our earlier expectations.
Profit before tax and exceptional items for the Group for the financial year to 31 March 2004 will depend upon the final outcome of the pricing negotiations in both the US and Europe and the translation impact of exchange rates. Nevertheless, we anticipate results will be close to market expectations with a weaker Amylum result in the final quarter being offset by a satisfactory performance in the rest of the business.
Looking forward, based on our current experience of raw material costs and contract negotiations to date, we expect Amylum’s results for the financial year to 31 March 2005 to be significantly below those of 2004. A review of Amylum’s operations is in hand in order further to reduce the cost base. Although we anticipate further progress in 2005 at our North American businesses, this is likely to be offset on currency translation.
Click here for our press image gallery
About Tate & Lyle PLC:
Supported by our 165-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients and solutions every day.
Through our leading expertise in sweetening, mouthfeel and fortification, we develop ingredients and solutions which reduce sugar, calories and fat, add fibre and protein, and provide texture and stability to food and drink in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.
Tate & Lyle recently acquired CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients to create a leader in mouthfeel, significantly enhancing our solutions capabilities. Following this combination, we now have more than 5,000 employees working in around 75 locations in 39 countries, serving customers in more than 120 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives through the Science of Food. By living our purpose, we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.
Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. For the year ended 31 March 2024, and on a pro forma basis which assumes for illustrative purposes that the combination with CP Kelco took place on 1 April 2023, revenue for the enlarged Tate & Lyle Group would have been £2.25 billion. For more information, please visit www.tateandlyle.com or follow Tate & Lyle on LinkedIn, X (Twitter), Facebook or YouTube